

Anthony Howell, Howell A, Howell T

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4411918/publications.pdf>

Version: 2024-02-01

307
papers

28,675
citations

3449

93
h-index

6686

161
g-index

314
all docs

314
docs citations

314
times ranked

29885
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2010, 11, 1135-1141.	5.1	1,017
2	Adjuvant Docetaxel for Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 2302-2313.	13.9	892
3	Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. <i>Cancer</i> , 2003, 98, 1735-1744.	2.0	836
4	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4273-4278.	0.8	666
5	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1829-1834.	0.8	647
6	Breast Cancer Risk Genes α Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	13.9	532
7	Ketones and lactate α fuel α tumor growth and metastasis. <i>Cell Cycle</i> , 2010, 9, 3506-3514.	1.3	526
8	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282.	3.0	510
9	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2014, 383, 1041-1048.	6.3	504
10	Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. <i>Oncotarget</i> , 2015, 6, 4569-4584.	0.8	401
11	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution. <i>Cell Cycle</i> , 2010, 9, 3276-3296.	1.3	400
12	Evidence for a stromal-epithelial α lactate shuttle α in human tumors. <i>Cell Cycle</i> , 2011, 10, 1772-1783.	1.3	393
13	Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 1605-1613.	0.8	392
14	Autophagy in cancer associated fibroblasts promotes tumor cell survival. <i>Cell Cycle</i> , 2010, 9, 3515-3533.	1.3	377
15	Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 656-661.	1.1	376
16	Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. <i>Journal of Clinical Oncology</i> , 2008, 26, 1051-1057.	0.8	363
17	Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2011, 103, 744-752.	3.0	358
18	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology</i> , The, 2015, 16, 67-75.	5.1	349

#	ARTICLE	IF	CITATIONS
19	The effect of intermittent energy and carbohydrate restriction<i>v</i>. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. British Journal of Nutrition, 2013, 110, 1534-1547.	1.2	336
20	International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. Journal of Clinical Oncology, 2003, 21, 2600-2608.	0.8	322
21	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
22	A putative human breast stem cell population is enriched for steroid receptor-positive cells. Developmental Biology, 2005, 277, 443-456.	0.9	312
23	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. Cancer, 2003, 98, 229-238.	2.0	305
24	Ketones and lactate increase cancer cell â€œstemness,â€•driving recurrence, metastasis and poor clinical outcome in breast cancer. Cell Cycle, 2011, 10, 1271-1286.	1.3	295
25	Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 2004, 22, 4261-4271.	0.8	283
26	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. Journal of Clinical Oncology, 2010, 28, 3411-3415.	0.8	271
27	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ. Cell Cycle, 2011, 10, 4047-4064.	1.3	256
28	Warburg Meets Autophagy: Cancer-Associated Fibroblasts Accelerate Tumor Growth and Metastasis<i>via</i>Oxidative Stress, Mitophagy, and Aerobic Glycolysis. Antioxidants and Redox Signaling, 2012, 16, 1264-1284.	2.5	254
29	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Research, 2014, 16, 442.	2.2	252
30	Metabolic reprogramming of cancer-associated fibroblasts by TGF-Î² drives tumor growth: Connecting TGF-Î² signaling with â€œWarburg-likeâ€•cancer metabolism and L-lactate production. Cell Cycle, 2012, 11, 3019-3035.	1.3	249
31	Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. Annual Review of Pathology: Mechanisms of Disease, 2012, 7, 423-467.	9.6	249
32	The autophagic tumor stroma model of cancer. Cell Cycle, 2010, 9, 3485-3505.	1.3	248
33	Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446.	2.2	248
34	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, The, 2013, 14, 989-998.	5.1	246
35	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect. Cell Cycle, 2011, 10, 2504-2520.	1.3	245
36	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 2010, 9, 2423-2433.	1.3	238

#	ARTICLE	IF	CITATIONS
37	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. <i>Breast Cancer Research and Treatment</i> , 1997, 45, 121-133.	1.1	235
38	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 111-116.	1.1	219
39	Quality of Life of Postmenopausal Women in the ATAC (Arimidex, Tamoxifen, Alone or in T) Trial. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 273-284.	1.1	218
40	Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1045-1051.	1.2	218
41	Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2001, 19, 1885-1892.	0.8	214
42	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008, 34, S3-S18.	3.4	209
43	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production. <i>Cell Cycle</i> , 2012, 11, 2285-2302.	1.3	209
44	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis. <i>Cell Cycle</i> , 2011, 10, 2440-2449.	1.3	208
45	HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells. <i>Cell Cycle</i> , 2010, 9, 3534-3551.	1.3	207
46	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology</i> , 2011, 12, 496-503.	5.1	196
47	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. <i>Psycho-Oncology</i> , 2004, 13, 61-66.	1.0	195
48	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. <i>BMC Cancer</i> , 2008, 8, 155.	1.1	191
49	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. <i>Breast Cancer Research</i> , 2015, 17, 147.	2.2	186
50	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, fueling tumor growth via paracrine interactions, without an increase in neo-angiogenesis. <i>Cell Cycle</i> , 2012, 11, 3599-3610.	1.3	182
51	Understanding the "lethal" drivers of tumor-stroma co-evolution. <i>Cancer Biology and Therapy</i> , 2010, 10, 537-542.	1.5	180
52	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007, 14, 169-187.	1.6	165
53	The autophagic tumor stroma model of cancer or "battery-operated tumor growth". <i>Cell Cycle</i> , 2010, 9, 4297-4306.	1.3	165
54	Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. <i>Cell Reports</i> , 2015, 12, 1968-1977.	2.9	164

#	ARTICLE	IF	CITATIONS
55	Mitochondrial metabolism in cancer metastasis. <i>Cell Cycle</i> , 2012, 11, 1445-1454.	1.3	162
56	Firm R&D, innovation and easing financial constraints in China: Does corporate tax reform matter?. <i>Research Policy</i> , 2016, 45, 1996-2007.	3.3	159
57	Estrogen responsiveness and control of normal human breast proliferation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998, 3, 23-35.	1.0	157
58	Origins of breast cancer subtypes and therapeutic implications. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 516-525.	4.3	155
59	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. <i>Cancer</i> , 2005, 104, 236-239.	2.0	154
60	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 924-938.	1.5	154
61	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. <i>Breast Cancer Research</i> , 2011, 13, 213.	2.2	153
62	Ketone body utilization drives tumor growth and metastasis. <i>Cell Cycle</i> , 2012, 11, 3964-3971.	1.3	152
63	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 866-873.	6.3	149
64	Mitochondria "fuel" breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. <i>Cell Cycle</i> , 2012, 11, 4390-4401.	1.3	147
65	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 1085-1097.	1.5	145
66	Energy transfer in "parasitic" cancer metabolism. <i>Cell Cycle</i> , 2011, 10, 4208-4216.	1.3	144
67	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 135-142.	1.1	144
68	Breast cancer risk-assessment models. <i>Breast Cancer Research</i> , 2007, 9, 213.	2.2	142
69	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. <i>European Journal of Cancer</i> , 2006, 42, 1143-1150.	1.3	139
70	Cytokine production and inflammation drive autophagy in the tumor microenvironment. <i>Cell Cycle</i> , 2011, 10, 1784-1793.	1.3	137
71	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". <i>Aging</i> , 2010, 2, 185-199.	1.4	136
72	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2318-2324.	1.1	132

#	ARTICLE	IF	CITATIONS
73	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. <i>Cell Cycle</i> , 2010, 9, 2412-2422.	1.3	130
74	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 47-66.	2.2	124
75	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment. <i>Cancer Biology and Therapy</i> , 2011, 11, 383-394.	1.5	122
76	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. <i>Journal of Pathology</i> , 1992, 167, 25-32.	2.1	120
77	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
78	Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. <i>International Journal of Cancer</i> , 1991, 48, 206-210.	2.3	117
79	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. <i>Cell Cycle</i> , 2012, 11, 2272-2284.	1.3	116
80	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006, 13, 273-278.	1.6	115
81	Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1329-1336.	3.0	114
82	Mitochondrial Fission Induces Glycolytic Reprogramming in Cancer-Associated Myofibroblasts, Driving Stromal Lactate Production, and Early Tumor Growth. <i>Oncotarget</i> , 2012, 3, 798-810.	0.8	112
83	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth. <i>Cell Cycle</i> , 2011, 10, 4065-4073.	1.3	110
84	Picking 'winners' in China: Do subsidies matter for indigenous innovation and firm productivity?. <i>China Economic Review</i> , 2017, 44, 154-165.	2.1	110
85	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. <i>JAMA Oncology</i> , 2018, 4, 476.	3.4	109
86	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). <i>Lancet Oncology</i> , The, 2008, 9, 953-961.	5.1	108
87	Two-compartment tumor metabolism: Autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. <i>Cell Cycle</i> , 2012, 11, 2545-2559.	1.3	107
88	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. <i>Cell Cycle</i> , 2012, 11, 4174-4180.	1.3	105
89	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. <i>Cancer Prevention Research</i> , 2012, 5, 943-951.	0.7	104
90	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 773-779.	5.1	103

#	ARTICLE	IF	CITATIONS
91	Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. <i>Cell Cycle</i> , 2012, 11, 3956-3963.	1.3	103
92	Pure oestrogen antagonists for the treatment of advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 689-706.	1.6	100
93	Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. <i>International Journal of Cancer</i> , 2002, 101, 555-559.	2.3	99
94	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. <i>Cancer Biology and Therapy</i> , 2011, 12, 1101-1113.	1.5	99
95	Understanding the metabolic basis of drug resistance. <i>Cell Cycle</i> , 2011, 10, 2521-2528.	1.3	97
96	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. <i>Breast Cancer Research</i> , 2008, 10, R26.	2.2	88
97	Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. <i>International Journal of Cancer</i> , 2007, 121, 1017-1020.	2.3	86
98	Migration and Inequality in Xinjiang: A Survey of Han and Uyghur Migrants in Urumqi. <i>Eurasian Geography and Economics</i> , 2011, 52, 119-139.	1.7	84
99	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 279-287.	1.1	80
100	Metabolic reprogramming and two-compartment tumor metabolism. <i>Cell Cycle</i> , 2012, 11, 3280-3289.	1.3	77
101	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 318-328.	3.4	77
102	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. <i>Breast Cancer Research</i> , 2015, 17, 143.	2.2	77
103	Mitochondrial dysfunction in breast cancer cells prevents tumor growth. <i>Cell Cycle</i> , 2013, 12, 172-182.	1.3	76
104	Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. <i>Clinical Cancer Research</i> , 2006, 12, 7025-7032.	3.2	75
105	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012, 14, R57.	2.2	75
106	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment. <i>Cell Cycle</i> , 2013, 12, 2580-2597.	1.3	75
107	Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e66-e73.	1.8	75
108	The impact of China's R&D subsidies on R&D investment, technological upgrading and economic growth. <i>Technological Forecasting and Social Change</i> , 2022, 174, 121212.	6.2	75

#	ARTICLE	IF	CITATIONS
109	Oestrogen and breast cancer: results from the WHI trial. <i>Lancet Oncology</i> , The, 2012, 13, 437-438.	5.1	74
110	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. <i>Breast Cancer Research</i> , 2014, 16, 451.	2.2	74
111	Steroid receptors in human breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 316-323.	3.1	73
112	Breast cancer risk feedback to women in the UK NHS breast screening population. <i>British Journal of Cancer</i> , 2016, 114, 1045-1052.	2.9	73
113	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>World Development</i> , 2017, 94, 200-211.	2.6	73
114	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment. <i>Cell Cycle</i> , 2012, 11, 4402-4413.	1.3	71
115	Matrix remodeling stimulates stromal autophagy, fueling cancer cell mitochondrial metabolism and metastasis. <i>Cell Cycle</i> , 2011, 10, 2021-2034.	1.3	69
116	Accelerated aging in the tumor microenvironment. <i>Cell Cycle</i> , 2011, 10, 2059-2063.	1.3	63
117	Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. <i>Differentiation</i> , 1990, 42, 199-207.	1.0	62
118	Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. <i>Menopause International</i> , 2008, 14, 6-12.	1.6	61
119	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4266-4272.	0.8	61
120	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 611-618.	1.1	58
121	Indigenous innovation with heterogeneous risk and new firm survival in a transitioning Chinese economy. <i>Research Policy</i> , 2015, 44, 1866-1876.	3.3	58
122	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 743-750.	0.8	58
123	Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01. <i>Journal of Clinical Oncology</i> , 2005, 23, 8322-8330.	0.8	57
124	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. <i>Cell Cycle</i> , 2012, 11, 253-263.	1.3	57
125	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1460-1468.	5.1	56
126	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. <i>Journal of Medical Genetics</i> , 2017, 54, 111-113.	1.5	56

#	ARTICLE	IF	CITATIONS
127	Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015, 6, 4585-4601.	0.8	55
128	Hereditary ovarian cancer and two-compartment tumor metabolism. <i>Cell Cycle</i> , 2012, 11, 4152-4166.	1.3	53
129	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: Connecting fibrosis, inflammation, and stemness for cancer prevention. <i>Cell Cycle</i> , 2014, 13, 580-599.	1.3	52
130	Agglomeration, (un)related variety and new firm survival in China: Do local subsidies matter?. <i>Papers in Regional Science</i> , 2018, 97, 485-501.	1.0	52
131	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
132	Allelic imbalance on chromosome I in human breast cancer. II. Microsatellite repeat analysis. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 24-31.	1.5	51
133	Fulvestrant (Faslodex™): Current and future role in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 265-273.	2.0	51
134	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. <i>Cell Cycle</i> , 2013, 12, 818-825.	1.3	51
135	Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 409-411.	0.9	49
136	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens. <i>Breast Cancer Research</i> , 2004, 6, 269-74.	2.2	49
137	Ethnic entrepreneurship, initial financing, and business performance in China. <i>Small Business Economics</i> , 2019, 52, 697-712.	4.4	49
138	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 727-734.	1.1	47
139	Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. <i>International Journal of Cancer</i> , 1994, 59, 25-32.	2.3	46
140	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4284-4294.	0.8	45
141	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	3.0	45
142	Pharmacokinetics of oral and intravenous fluorouracil in humans. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 1428-1431.	1.6	44
143	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism. <i>Cell Cycle</i> , 2013, 12, 289-301.	1.3	43
144	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. <i>Breast Cancer Research and Treatment</i> , 1996, 41, 31-41.	1.1	42

#	ARTICLE	IF	CITATIONS
145	Vascular effects of aromatase inhibitors: Data from clinical trials. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 95, 143-149.	1.2	42
146	Metabolic remodeling of the tumor microenvironment: Migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. <i>Cell Cycle</i> , 2012, 11, 3403-3414.	1.3	42
147	Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 307-317.	1.1	41
148	Biomarkers of Dietary Energy Restriction in Women at Increased Risk of Breast Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 720-731.	0.7	41
149	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. <i>British Journal of Cancer</i> , 2018, 118, 1648-1657.	2.9	41
150	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1 α , autophagy and ketone body production. <i>Cell Cycle</i> , 2012, 11, 4167-4173.	1.3	40
151	Reverse Warburg Effect in a Patient With Aggressive B-Cell Lymphoma: Is Lactic Acidosis a Paraneoplastic Syndrome?. <i>Seminars in Oncology</i> , 2013, 40, 403-418.	0.8	40
152	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017, 35, 2666-2673.	0.8	40
153	Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 1987, 19, 138-42.	1.1	39
154	Industry relatedness, FDI liberalization and the indigenous innovation process in China. <i>Regional Studies</i> , 2020, 54, 229-243.	2.5	39
155	The endocrine prevention of breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 615-623.	2.2	38
156	Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose. <i>Clinical Breast Cancer</i> , 2011, 11, 204-210.	1.1	38
157	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. <i>Cancer Prevention Research</i> , 2014, 7, 993-1001.	0.7	37
158	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. <i>Breast Cancer Research</i> , 2016, 18, 57.	2.2	37
159	White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018, 168, 326.	2.0	37
160	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet</i> , The, 2005, 365, 1449-1451.	6.3	36
161	Acute Chemotherapy-Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. <i>Clinical Cancer Research</i> , 2006, 12, 7033-7038.	3.2	36
162	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1191-1198.	1.1	36

#	ARTICLE	IF	CITATIONS
163	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	3.2	36
164	Breast cancer susceptibility variants alter risks in familial disease. <i>Journal of Medical Genetics</i> , 2010, 47, 126-131.	1.5	35
165	Agglomeration, absorptive capacity and knowledge governance: implications for public-private firm innovation in China. <i>Regional Studies</i> , 2020, 54, 1069-1083.	2.5	35
166	Do Women Understand the Odds? Risk Perceptions and Recall of Risk Information in Women with a Family History of Breast Cancer. <i>Public Health Genomics</i> , 2003, 6, 214-223.	0.6	34
167	Infiltrating lobular carcinoma of the breast: Response to endocrine therapy and survival. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 979-982.	0.9	33
168	Are aromatase inhibitors superior to antiestrogens?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 93, 237-247.	1.2	33
169	Energy restriction and the prevention of breast cancer. <i>Proceedings of the Nutrition Society</i> , 2012, 71, 263-275.	0.4	33
170	Fulvestrant (Faslodex [®]): current status in the therapy of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 151-160.	1.1	31
171	Adjuvant aromatase inhibitors for breast cancer. <i>Lancet, The</i> , 2005, 366, 431-433.	6.3	31
172	The milk protein β -casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. <i>Cell Cycle</i> , 2012, 11, 3972-3982.	1.3	31
173	Breast cancer: Aromatase inhibitors take on tamoxifen. <i>Nature Medicine</i> , 2002, 8, 1341-1344.	15.2	30
174	Lung cancer after treatment for breast cancer. <i>Lancet Oncology, The</i> , 2010, 11, 1184-1192.	5.1	30
175	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 625-629.	1.1	30
176	Can the breast screening appointment be used to provide risk assessment and prevention advice?. <i>Breast Cancer Research</i> , 2015, 17, 84.	2.2	30
177	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 139-143.	0.8	30
178	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	5.8	30
179	Mechanisms of Disease: prediction and prevention of breast cancer cellular and molecular interactions. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 635-646.	4.3	29
180	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995, 345, 989-990.	6.3	28

#	ARTICLE	IF	CITATIONS
181	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. <i>Breast Cancer Research</i> , 2006, 8, 214.	2.2	28
182	Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 281-4.	1.1	27
183	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 79, 227-237.	1.2	27
184	Heterogeneous impacts of China's economic and development zone program. <i>Journal of Regional Science</i> , 2019, 59, 797-818.	2.1	27
185	Creating a tumor-resistant microenvironment: Cell-mediated delivery of TNF α completely prevents breast cancer tumor formation in vivo. <i>Cell Cycle</i> , 2013, 12, 480-490.	1.3	26
186	Beliefs about weight and breast cancer: an interview study with high risk women following a 12-month weight loss intervention. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 1.	0.6	25
187	Clinical development of fulvestrant (Faslodex TM). <i>Cancer Treatment Reviews</i> , 2005, 31, S3-S9.	3.4	23
188	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>Growth and Change</i> , 2011, 42, 200-226.	1.3	23
189	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. <i>International Journal of Cancer</i> , 2012, 131, 417-425.	2.3	23
190	Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. <i>Journal of Medical Genetics</i> , 2013, 50, 368-372.	1.5	23
191	The future of fulvestrant (Faslodex TM). <i>Cancer Treatment Reviews</i> , 2005, 31, S26-S33.	3.4	22
192	Hormone Replacement Therapy and Breast Cancer. <i>Recent Results in Cancer Research</i> , 2010, 188, 115-124.	1.8	22
193	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. <i>Familial Cancer</i> , 2014, 13, 189-196.	0.9	22
194	New developments in the treatment of postmenopausal breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 420-428.	3.1	21
195	The emerging breast cancer epidemic: early diagnosis and treatment. <i>Breast Cancer Research</i> , 2010, 12, S10.	2.2	21
196	Epithelial and Stromal MicroRNA Signatures of Columnar Cell Hyperplasia Linking Let-7c to Precancerous and Cancerous Breast Cancer Cell Proliferation. <i>PLoS ONE</i> , 2014, 9, e105099.	1.1	21
197	Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 25, 435-439.	1.1	20
198	Predicting Compliance in a Breast Cancer Prevention Trial. <i>Breast Journal</i> , 2006, 12, 446-450.	0.4	20

#	ARTICLE	IF	CITATIONS
199	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. Breast Cancer Research, 2003, 6, E7.	2.2	19
200	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. American Journal of Obstetrics and Gynecology, 2009, 200, 80.e1-80.e7.	0.7	19
201	Marshallian Sources of Relatedness and Their Effects on Firm Survival and Subsequent Success in China. Economic Geography, 2017, 93, 346-366.	2.1	19
202	Going out to innovate more at home: Impacts of outward direct investments on Chinese firms' domestic innovation performance. China Economic Review, 2020, 60, 101404.	2.1	19
203	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	3.6	19
204	Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days. Food Science and Nutrition, 2018, 6, 674-680.	1.5	18
205	Personalized prevention in high risk individuals: Managing hormones and beyond. Breast, 2018, 39, 139-147.	0.9	18
206	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. BMC Public Health, 2018, 18, 178.	1.2	18
207	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. Breast, 2018, 37, 148-153.	0.9	17
208	Breast tumour stroma is a prognostic indicator and target for therapy. Breast Cancer Research, 2009, 11, S16.	2.2	16
209	Uptake of breast cancer prevention and screening trials. Journal of Medical Genetics, 2010, 47, 853-855.	1.5	16
210	A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 391-394.	0.9	15
211	Overview of the impact of conventional systemic therapies on breast cancer. Endocrine-Related Cancer, 2005, 12, S9-S16.	1.6	15
212	Better Life Expectancy in Women with <i>BRCA2</i> Compared with <i>BRCA1</i> Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	1.1	15
213	Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. Journal of Medical Genetics, 2014, 51, 573-580.	1.5	15
214	Minimum wage impacts on Han-minority Workers' wage distribution and inequality in urban china. Journal of Urban Economics, 2020, 115, 103184.	2.4	15
215	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
216	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. Familial Cancer, 2007, 6, 287-294.	0.9	13

#	ARTICLE	IF	CITATIONS
217	Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4548-4550.	0.8	13
218	Increased Rate of Phenocopies in All Age Groups in <i>BRCA1</i> / <i>BRCA2</i> Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2269-2276.	1.1	13
219	A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 141-143.	0.9	11
220	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). <i>Lancet</i> , The, 1998, 352, 1222.	6.3	11
221	Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 302-309.	1.1	11
222	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. <i>Cell Cycle</i> , 2013, 12, 2935-2936.	1.3	11
223	Technological relatedness and asymmetrical firm productivity gains under market reforms in China. <i>Cambridge Journal of Regions, Economy and Society</i> , 0, , rsw024.	1.7	11
224	Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1719-1725.	0.9	10
225	Response and Resistance to the Endocrine Prevention of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 201-211.	0.8	10
226	The <i>Arimidex</i> , Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 207-215.	0.4	9
227	Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , 2006, 98, 643-643.	3.0	9
228	Are We Ready for Online Tools in Decision Making for <i>BRCA1/2</i> Mutation Carriers?. <i>Journal of Clinical Oncology</i> , 2012, 30, 471-473.	0.8	9
229	Can multiple SNP testing in <i>BRCA2</i> and <i>BRCA1</i> female carriers be used to improve risk prediction models in conjunction with clinical assessment?. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 87.	1.5	9
230	Recruitment to the <i>Breast</i> Activity and Healthy Eating After Diagnosis (B-AHEAD) Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2018, 17, 131-137.	0.8	9
231	Bayesian evaluation of breast cancer screening using data from two studies. <i>Statistics in Medicine</i> , 2003, 22, 1661-1674.	0.8	8
232	Normal Breast Tissue Implanted into Athymic Nude Mice Identifies Biomarkers of the Effects of Human Pregnancy Levels of Estrogen. <i>Cancer Prevention Research</i> , 2009, 2, 257-264.	0.7	8
233	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. <i>European Journal of Radiology</i> , 2017, 94, 133-139.	1.2	8
234	Socio-economic impacts of scaling back a massive payments for ecosystem services programme in China. <i>Nature Human Behaviour</i> , 2022, 6, 1218-1225.	6.2	8

#	ARTICLE	IF	CITATIONS
235	A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer. <i>Breast Journal</i> , 2003, 9, 213-222.	0.4	7
236	Early stopping of clinical trials. <i>Breast Cancer Research</i> , 2005, 7, 181-3.	2.2	7
237	Lack of caveolin-1 (P132L) somatic mutations in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1185-1186.	1.1	7
238	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	2.2	7
239	4 New endocrine approaches to breast cancer. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1990, 4, 67-84.	1.0	6
240	Adjuvant Use of Anastrozole in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1524-1526.	0.8	6
241	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007, 17, 210-219.	0.5	6
242	Breast cancer prevention: SERMs come of age. <i>Lancet</i> , The, 2013, 381, 1795-1797.	6.3	6
243	Innovation and Firm Performance in the People's Republic of China: A Structural Approach with Spillovers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
244	Explaining the urban premium in Chinese cities and the role of place-based policies. <i>Environment and Planning A</i> , 2020, 52, 1332-1356.	2.1	6
245	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. <i>Lecture Notes in Computer Science</i> , 2012, , 228-235.	1.0	6
246	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	2.0	6
247	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. <i>International Journal of Cancer</i> , 2003, 103, 686-692.	2.3	5
248	An early peak of relapse after surgery for breast cancer. <i>Breast Cancer Research</i> , 2004, 6, 255-7.	2.2	5
249	Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: More Trouble With Phenocopies. <i>Journal of Clinical Oncology</i> , 2012, 30, 1142-1143.	0.8	5
250	Marshallian Sources of Relatedness, Technological Capabilities and Firm Productivity in China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	5
251	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 591-596.	1.1	5
252	Picking 'winners' in space: Impact of spatial targeting on firm performance in China. <i>Journal of Regional Science</i> , 2020, 60, 1025-1046.	2.1	5

#	ARTICLE	IF	CITATIONS
253	The therapeutic potential of novel aromatase inhibitors in breast cancer. Expert Opinion on Investigational Drugs, 1999, 8, 269-279.	1.9	4
254	Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. BMC Medicine, 2010, 8, 73.	2.3	4
255	Same task, same observers, different values: the problem with visual assessment of breast density. , 2013, , .		4
256	Do Marshallian Sources Drive Technological Relatedness? Implications for Firm Survival And Subsequent Success in China. SSRN Electronic Journal, 2016, , .	0.4	4
257	Title is missing!. Annals of Oncology, 2000, 11, 255-266.	0.6	4
258	“Should I Take HRT, Doctor?” Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. The Journal of the British Menopause Society, 1995, 1, 9-17.	1.3	3
259	Tamoxifen versus the newer SERMs: what is the evidence?. Annals of Oncology, 2000, 11, 255-266.	0.6	3
260	Strategies for Managing Breast Cancer Risk After the Menopause. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 289-307.	1.8	3
261	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: Therapeutic implications. Cell Cycle, 2013, 12, 2534-2534.	1.3	3
262	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time. , 2017, , .		3
263	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66.	1.1	3
264	Urban Agglomeration, Selection and the Impact of Policy Distortions on Firm Productivity in China. SSRN Electronic Journal, 0, , .	0.4	3
265	Inter-Industry Relatedness, Absorptive Capacity and Firm Productivity in a Transitioning Chinese Economy. SSRN Electronic Journal, 0, , .	0.4	3
266	Should lifestyle modifications be promoted to prevent breast cancer?. Breast Cancer Research, 2008, 10, S11.	2.2	2
267	10-year analysis of the ATAC trial: wrong conclusion? “ Authors' reply. Lancet Oncology, The, 2011, 12, 217.	5.1	2
268	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. SSRN Electronic Journal, 0, , .	0.4	2
269	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. Breast Cancer Research and Treatment, 2015, 152, 87-94.	1.1	2
270	Local mammographic density as a predictor of breast cancer. Proceedings of SPIE, 2015, , .	0.8	2

#	ARTICLE	IF	CITATIONS
271	No strong evidence for increased risk of breast cancer 8–26 years after multiple mammograms in their 30s in females at moderate and high familial risk. <i>British Journal of Radiology</i> , 2016, 89, 20150960.	1.0	2
272	Clustering effects on firm exporting with productivity-enhancing R&D in China. <i>World Economy</i> , 2019, 42, 3168-3187.	1.4	2
273	Minimum Wage Impacts on Inequality, Job Formality and the Ethnic Wage Gap in Urban China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
274	Use of Volumetric Breast Density Measures for the Prediction of Weight and Body Mass Index. <i>Lecture Notes in Computer Science</i> , 2014, , 282-289.	1.0	2
275	The Relationship between Age and the Effect of Adjuvant Therapies in Women with Primary Breast Cancer. <i>Hormone Research</i> , 1989, 32, 231-237.	1.8	1
276	Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005, 17, 429-434.	0.9	1
277	Does HER2 overexpression affect response to endocrine therapy in advanced cancer?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 78-79.	4.3	1
278	Defining bad stroma in human breast tumors. <i>Cell Cycle</i> , 2011, 10, 3056-3056.	1.3	1
279	Genesis and Outcome of a Breast Cancer Trial to Develop the Aromatase Inhibitor Anastrozole. <i>Clinical Chemistry</i> , 2012, 58, 782-783.	1.5	1
280	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. <i>Breast Cancer Research</i> , 2013, 15, 401.	2.2	1
281	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	1
282	Clustering Effects on Firm Exporting with Productivity-Enhancing R&D in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
283	Identifying the Sources of Agglomeration Benefits within China's Economic and Development Zones. <i>SSRN Electronic Journal</i> , 2017, , .	0.4	1
284	Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. <i>Journal of Medical Genetics</i> , 2018, 55, 442-448.	1.5	1
285	Relatedness economies, absorptive capacity, and economic catch-up: firm-level evidence from China. <i>Industrial and Corporate Change</i> , 2019, , .	1.7	1
286	A Structural Model of Indigenous Innovation and Catch-Up for Developing Economies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
287	Ethnicity, Start-Up Finance, and Entrepreneurship in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
288	Direct and Spillover Effects of Targeted Cash Transfers on Ethnic Rural-Urban Migration in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
289	The Origin of Estrogen Receptor \hat{I} -Positive and \hat{I} -Negative Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 79-86.	0.8	1
290	Picking Winners in China: Do Subsidies Matter for Indigenous Innovation and Firm Productivity?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
291	Mammographic Density Over Time in Women With and Without Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2016, , 291-298.	1.0	1
292	Clarification of Anastrozole/Megestrol Acetate Trial Program Design. <i>Journal of Clinical Oncology</i> , 2000, 18, 4109-4109.	0.8	0
293	Spreading the word, but not too thinly. <i>Lancet</i> , The, 2004, 363, 165-166.	6.3	0
294	The Group Room. <i>Lancet Oncology</i> , The, 2005, 6, 268.	5.1	0
295	Morrow M, Jordan VC: <i>Managing Breast Cancer Risk</i> . 1st Edition. Hamilton, Ontario: BC Decker Inc. <i>Breast Cancer Research</i> , 2005, 7, 1.	2.2	0
296	Risk factors. Introduction to Session 1. <i>Breast Cancer Research</i> , 2009, 11, S2.	2.2	0
297	Detection and management of women at increased risk of breast cancer. <i>Clinical Practice (London, England)</i> Tj ETQq1 1 0.784314 rgBT /Overl 0.1	0.1	0
298	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. <i>Proceedings of SPIE</i> , 2017, 10134, .	0.8	0
299	Does the prediction of breast cancer improve using a combination of mammographic density measures compared to individual measures alone?. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0
300	Reply to Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial". <i>British Journal of Cancer</i> , 2020, 122, 925-926.	2.9	0
301	<i>Endocrine Therapy</i> . , 2010, , 329-352.		0
302	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187.		0
303	Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. <i>Lecture Notes in Computer Science</i> , 2016, , 540-547.	1.0	0
304	Variations in Breast Density and Mammographic Risk Factors in Different Ethnic Groups. <i>Lecture Notes in Computer Science</i> , 2016, , 510-517.	1.0	0
305	Minimum Wages, Spillovers and the Unconditional Wage Distribution in Urban China: Do Ethnic Minorities Benefit?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
306	Heterogenous Impacts of China's Economic and Development Zone Program. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
307	Reader performance in visual assessment of breast density using visual analogue scales: are some readers more predictive of breast cancer?. , 2018, , .		0